Skip to main content

Epigenetic Mechanisms and Their Involvement in Rare Diseases, Volume II

43kviews
Editorial20 September 2024
Editorial: Epigenetic mechanisms and their involvement in rare diseases, volume II

This current research topic includes articles on the epigenetic basis of rare neurological diseases that are authored by Tom Moss and collogues 2023 [2]; Roberts et al., 2024 [3]; as well as the impact of epigenetic in other rare diseases covered by Fu et al. 2023 [4]; and Lyu et al., 2023 [5].In a comprehensive review, Moss et al., discusses the UBTF E210K neuroregression syndrome as part of ribosomopathy diseases. The authors focus on UBF that is an epigenetic regulator of ribosomal DNA (rDNA) genes, and a transcriptional regulator acting at the level of chromatin structure. Indeed, UBF controls the open chromatin state at the rDNA genes and a basal trans-acting factor directing rRNA transcription by RNA Polymerase I. Through a series of interesting concepts on rRNA transcription, the authors cover a large volume of current literature on 47S primary rRNA transcription and processing into smaller mature rRNA molecules. They comprehensively discuss UBF as a multi-HMGB-box protein and the role of different variants in human disease. This article is further complemented with five illustrations that are elegantly designed to capture the main points of this manuscript [2].In a recent article, Roberts at al., review the main epigenetic mechanisms that are involved in rare neurological diseases. This manuscript starts with a definition of rare diseases and an illustration of the prevalence of a disease to be considered as "rare disease" based on the geographic location around the world. The authors provide a comprehensive and up-to-date overview of the etiology, clinical symptoms, associated epigenetic basis, and genetic causes of selected neurological diseases. This includes the following diseases: Rett Syndrome, Rubinstein-Taybi Syndrome, Angelman syndrome, Prader-Willi Syndrome, and Huntington's disease. The article includes six Figures and a Table . As an example of a rare disease, for Rett Syndrome that is caused by MECP2 mutation, the authors describe the functional role of MeCP2 protein and its isoforms, different developmental stages of the disease, MECP2 gene structure, the impact of its genetic mutations on the functional role of MeCP2 as a DNA methylationbinding protein, its regulatory role on RNA splicing and the global epigenomics of brain cells. Additional discussions on MeCP2 protein function includes regulation of the chromatin structure, ribosomal targets, and potential impact on other epigenetic modifications [3].

. The authors present a global perspective and discuss the application of next generation sequencing and bioinformatics in the associated pathophysiology in the affected patients. In the comprehensively prepared Table 1 of the article, they highlight the role of DNA methylation, histone PTM, and other modes of epigenetic regulations such as chromatin remodeling, in association with epigenetic factors, the causative genetic basis, for specific cases of RDEOs. For each of these rare diseases of epigenetic origin, the OMIM entry is also presented. The authors further discuss the challenges in the study of rare diseases of epigenetic origin and the potential opportunities. This article is complemented with two well-designed illustrations [4].In another article, Lyu and collogues provide an overview of the role of DNA modifications in liver fibrosis. The authors discuss the pathogenesis of hepatic fibrosis description of liver fibrosis, as a repair mechanism for the damage and injury of liver. They then present evidence from published literature to link this process to DNA methylation. The article covers the basis of hepatic stellate cell activation in case of liver damage and/or inflammation. Specific factors and cell signaling pathways are discussed that play key roles in this process. This article presents an overview on the application of nucleoside and nonnucleoside analogs in terms of their usage in inhibiting DNA methylation. Discussed inhibitors of DNA methylation from the nucleoside group include: 5-Azacytidine and 5-Aza-deoxycytidine, Zebularine, and Guadecitabine. The authors also discuss non-nucleoside analogs that are inhibitors of DNA methylation. This article is complemented with a Figure that shows connection between liver injury, activation of hepatic stellate cells, DNA methylation, and gene regulation [5].

1,663 views

Epigenetics in rare neurological diseases
REVIEW
23 July 2024
Epigenetics in rare neurological diseases
Chris-Tiann Roberts, 3 more and Mojgan Rastegar
Rare neurological diseases include a vast group of heterogenous syndromes with primary impairment(s) in the peripheral and/or central nervous systems. Such rare disorders may have overlapping phenotypes, despite their distinct genetic etiology. One unique aspect of rare neurological diseases is their potential common association with altered epigenetic mechanisms.Epigenetic mechanisms include regulatory processes that control gene expression and cellular phenotype without changing the composition of the corresponding DNA sequences. Epigenetic factors include three types of proteins, the "readers, writers, and erasers" of DNA and DNA-bound proteins. Thus, epigenetic impairments of many neurological diseases may contribute to their pathology and manifested phenotypes. Here, we aim to provide a comprehensive review on the general etiology of selected rare neurological diseases, that include Rett Syndrome, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Huntington's disease, and Angelman syndrome, with respect to their associated aberrant epigenetic mechanisms.

8,715 views

14 citations

4,212 views

10 citations

CORRECTION
11 August 2023
Corrigendum: Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis
Shi-Yi Lyu, 7 more and Yong-Heng Luo

1,771 views

5 citations

Rare diseases of epigenetic origin: Challenges and opportunities
Rare diseases (RDs), more than 80% of which have a genetic origin, collectively affect approximately 350 million people worldwide. Progress in next-generation sequencing technology has both greatly accelerated the pace of discovery of novel RDs and provided more accurate means for their diagnosis. RDs that are driven by altered epigenetic regulation with an underlying genetic basis are referred to as rare disorders of epigenetic origin (RDEOs). These diseases pose unique challenges in research, as they often show complex genetic and clinical heterogeneity arising from unknown gene–disease mechanisms. Furthermore, multiple other factors, including cell type and developmental time point, can confound attempts to determine the pathophysiology of these disorders. These challenges are further exacerbated by factors that contribute to epigenetic variability and the difficulty of collecting sufficient participant numbers in human studies. However, new molecular and bioinformatics techniques will provide insight into how these disorders manifest over time. This review highlights recent studies addressing these challenges with innovative solutions. Further research will elucidate the mechanisms of action underlying unique RDEOs and facilitate the discovery of treatments and diagnostic biomarkers for screening, thereby improving health trajectories and clinical outcomes of affected patients.

12,106 views

33 citations

REVIEW
28 March 2023
Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis
Shi-Yi Lyu, 7 more and Yong-Heng Luo

6,171 views

26 citations